PDCD1 and cancer: As immunotherapy has ushered in a new era in the treatment of GC, PD-1 inhibitors have become the standard treatment for PD-L1 positive advanced GC, and further studies on immune-related biomarkers and their interactions with other cancer-related pathways are necessary.